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Abstract
This article presents a multiple imputation method for sensitivity analyses of time-to-event data
with possibly informative censoring. The imputed time for censored values is drawn from the
failure time distribution conditional on the time of follow-up discontinuation. A variety of
specifications regarding the post-discontinuation tendency of having events can be incorporated in
the imputation through a hazard ratio parameter for discontinuation versus continuation of follow-
up. Multiple-imputed data sets are analyzed with the primary analysis method, and the results are
then combined using the methods of Rubin. An illustrative example is provided.
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1. INTRODUCTION
An essential property of confirmatory clinical trials is the randomization of patients so that
the control and the test treatment have statistically equivalent distributions for known and
unknown baseline characteristics that may have potential associations with the outcome of
interest (National Research Council, 2010; CHMP, 2010). However, a ubiquitous and
inevitable problem that can undermine the comparability of randomized treatment groups is
potential bias from the nature and extent of missing data for patients who prematurely
discontinue their planned follow-up period for the assigned treatment (or the study) without
further assessment. In view of this problem, the design of many clinical trials specifies
continued follow-up of patients after premature termination of the assigned treatment for
such reasons as adverse events, lack of compliance, lack of efficacy, or protocol deviations.
A rationale for this practice is that it provides potentially useful information about the
Copyright © Taylor & Francis Group, LLC
Address correspondence to Yue Zhao, PhD, Merck Research Laboratories, 351 North Sumneytown Pike, North Wales, PA 19454;
yue.zhao4@merck.com.
Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/lbps.
NIH Public Access
Author Manuscript
J Biopharm Stat. Author manuscript; available in PMC 2014 May 05.
Published in final edited form as:






















experiences of these patients for their remaining follow-up time until their planned (or
premature) discontinuation from the study (Flyer and Hirman, 2009; Walton, 2009).
However, the role of this information can be unclear when patients receive effective rescue
treatment after discontinuing their assigned treatment (Flyer and Hirman, 2009). For
example, the comparison of regimens that begin with test treatment or placebo followed by
effective rescue therapy after their discontinuation could erroneously suggest that an
ineffective test treatment is effective solely because it forces more patients to switch to
rescue therapy than placebo (Permutt and Pinheiro, 2009). Thus, in such situations, analyses
for the comparison of the assigned treatments may need to ignore any unclear information
subsequent to their discontinuation and thereby proceed with the corresponding experiences
of patients as if missing.
Analytical strategies for drawing inferences from incomplete data rely on untestable
assumptions about the missing data distributions and the missingness mechanism (National
Research Council, 2010; CHMP, 2010). Little and Rubin (2002) classified the missing data
mechanism into three categories: missing completely at random (MCAR), missing at
random (MAR), and missing not at random (MNAR). When the data are MCAR, the
missing data are unrelated to the observed and unobserved study variables, so the observed
data are statistically representative for the experiences of all randomized patients. In
practice, however, MCAR is usually an unrealistic assumption. When the data are MAR, the
missingness depends only upon the observed study variables. That is, conditional on the
observed study variables, the probability of missing does not depend on the values of the
missing data. When the missingness probability also depends on the values of the missing
data, the data are said to be MNAR. In many situations, the MAR paradigm is realistic for
the primary analysis in confirmatory clinical trials (Zhang, 2009; Mallinckrodt et al., 2008).
However, the observed data can never rule out the possibility of MNAR. Therefore,
sensitivity analyses exploring the implications of departures from the primary MAR
assumption are always of interest to assess the robustness of the treatment effect inferences.
We consider randomized clinical trials where a time-to-event is the primary outcome.
Conventional methods such as the Kaplan–Meier estimation of survival curves (Kaplan and
Meier, 1958), the logrank or Wilcoxon tests (Mantel, 1966; Gehan, 1965), and the Cox
proportional hazards model (Cox, 1972) are frequently employed to describe time, to, event
distributions and to assess treatment effects. Missing data for a time-to-event occurs for
patients who prematurely discontinue follow-up for the assigned treatment (or the study)
prior to the occurrence of the event or the end of their planned follow-up period (or the
administrative closing date of the study). One way to address this type of missing data is to
censor the follow-up times of such patients at their times of premature discontinuation. Such
censoring is noninformative in a sense like the MAR assumption (Heitjan, 1994) when the
assumption of its independence from the possibly unobserved time-to-event applies: that is,
the possibly unknown true time to the event for a patient is the same regardless of whether
or not it is actually observed (or whether censoring occurs or not prior to it). Unfortunately,
the conventional MAR-like methods ignore the fact that the patients who discontinue the
assigned treatment no longer receive it after discontinuation. Instead, they attempt to
estimate what would be expected for the study if all patients remained on their assigned
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treatments until the occurrence of the event or the end of their planned follow-up period
(Flyer, 2009).
Alternatively, discontinuation from treatment can be specified as clinical failure when the
event of interest is unfavorable (Flyer and Hirman, 2009). In this case, one has a composite
endpoint (i.e., time to the event of interest or discontinuation), and it expresses the time
period for which a patient has had favorable experience with treatment. The application of
this method to both the control and the test treatment groups produces what can be called the
worst-case analysis, because patients who discontinue treatment are managed as having
much higher risk of a future event than other patients (Rothmann et al., 2009). In contrast,
the method in which a control patient who discontinues treatment has his or her follow-up
time censored at the time of discontinuation and such a test treatment patient is managed as
having the event is known as a worst-comparison analysis (Rothmann et al., 2009). The
result from the worst-comparison analysis provides a stringent boundary on the impact of
patients who discontinued treatment. Both the worst-case analysis and the worst-comparison
analysis have potentially unclear relevance for a study because they both make unrealistic
assumptions (Wittes, 2009). Usually, they are not designated as the primary analysis, but
they can be used as sensitivity analyses with the worst-comparison analysis invoking
maximal stress to the robustness of the study results (Walton, 2009). If the study conclusions
are not altered by such methods, then one is reassured regarding the validity of the primary
MAR-like analysis. Nevertheless, many studies will not maintain robustness to such
sensitivity analyses. Hence, these methods are often criticized as unrealistically stringent and
potentially problematic for a promising therapy to show effectiveness (Yan et al., 2009).
For longitudinal data with discontinuing patients, Little and Yau (1996) proposed multiple
imputation of the missing responses on the basis of models incorporating actual treatment
doses that might apply, or imputed doses under a variety of plausible assumptions. Recently,
using a similar basic approach, Roger (2008) developed a sensitivity analysis, where the
estimates from a mixed-effects model in the placebo group were used to provide information
about possible future behaviors of discontinued patients from the test treatment. In this
article, we propose a related sensitivity analysis for time-to-event data. On the basis of
Kaplan–Meier (KM) estimators (or Cox proportional hazards model counterparts), patients
who discontinue their assigned treatment (or follow-up) have multiple imputations for their
experiences during their unobserved remaining times until the planned end of their follow-
up period (as if they continued to be followed). The imputed data sets, having only
administrative censoring of follow-up for patients who did not have the event by the end of
their planned follow-up period, can then be analyzed by the standard methods for right
censored time-to-event data. A key feature of this multiple imputation method for sensitivity
analyses is a corresponding hazard ratio parameter θ for how the conditional survival
distribution for the missing extent of follow-up can allow for different post-discontinuation
behaviors of patients from the placebo and the test treatment groups. One can then
investigate the impact of departures from the primary missingness assumption (i.e.,
noninformative independent censoring) by summarizing the treatment effect as a function of
θ over a plausible range. This multiple imputation method is an extension and modification
of the work by Taylor et al. (2002), where the conditional KM estimators were used to
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impute failure times for survival analyses under a specification for non-informative
censoring.
The implementation of this method is illustrated with data from a clinical trial in psychiatry.
2. CLINICAL TRIAL EXAMPLES
For illustrative purposes, we consider time-to-event data based on a clinical trial pertaining
to maintenance treatment for bipolar disorder (Calabrese et al., 2003). For reasons related to
the confidentiality of the data from this clinical trial, the example in this article is based on a
random sample (with replacement) of 150 patients with the test treatment and 150 patients
with placebo. The study design for this clinical trial had an 8 to 16 weeks run-in period
within which all patients received test treatment. Eligible patients who tolerated and adhered
to this therapy were randomized to the test treatment or to the placebo, and then followed for
up to 76 weeks as the planned follow-up period. Accordingly, this study had a randomized
withdrawal design, and the primary efficacy endpoint was the time to intervention for any
mood episode.
In total, 97 (32 33%) patients discontinued the study prematurely (35% on placebo and 29%
on test treatment). Cumulative proportions of discontinued patients are shown in Fig. 1
(which has the convention of managing the patients who completed the study with the
primary event as having imputed follow-up of 76 weeks without premature discontinuation).
Discontinuations predominantly occurred before 35 weeks with higher cumulative
proportions for the placebo group. The documented reasons for discontinuation are
summarized in Table 1, although except perhaps for “adverse events,” they are not
informative about possible missing data mechanisms. The cumulative proportions of
discontinuation by those reasons are displayed for each treatment arm in Fig. A-1 of the
appendix. For an informal evaluation of the association of discontinuation with treatments,
patients’ demographics, and baseline psychiatric assessments, we used logistic regression
models for the odds of discontinuation versus completion of the study (either with the
primary outcome or completion of 76 weeks of follow-up without it). As shown in Table 2,
neither the unadjusted (from univariate regression on each individual variable) nor the
adjusted (from multivariate regression on all the variables) odds ratios have p-values below
0.05 for any of the baseline variables or treatments. However, in view of the substantial
extent of discontinuations, sensitivity analyses to address the robustness of conclusions to
the management of missing information are of interest.
The primary time-to-event analysis for this example has censoring of follow-up time for
patients with premature discontinuation of treatment, so it has the MAR-like assumption of
noninformative independent censoring. The previously noted worst-case analysis and the
worst-comparison analysis serve as sensitivity analyses. The Cox proportional hazards
model with one explanatory variable for treatment is used to obtain an unadjusted hazard
ratio. The nonparametric logrank and Wilcoxon tests are also used to compare the test
treatment and placebo. The results from these analyses are summarized in rows 1A, 1B, and
1C of Table 3, and they are interpretable as indicating superiority of the test treatment. The
worst-case analysis provides stronger results in favor of test treatment, whereas the worst-
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comparison analysis shows no treatment difference. The worst-case analysis tends to
overstate the difference in favor of the test treatment because the placebo group has more
prematurely discontinued patients. Conversely, the worst-comparison analysis excessively
understates the difference in favor of test treatment by unrealistically managing all of its
patients with premature discontinuation as having events at the time of discontinuation.
Therefore, more realistic approaches are worthy of consideration for sensitivity analyses to
address robustness of conclusions for a clinical trial like this example to possibly
informative censoring of time-to-event data.
3. METHOD
In most clinical trials with time-to-event data, a primary analysis that has censoring of
follow-up time for patients with premature discontinuation of treatment is generally
reasonable. The primary MAR-like assumption for such analysis is noninformative
independent censoring. The proposed sensitivity analysis in this article addresses the
implications of departures from this assumption by imputing different outcomes for the
patients with premature discontinuation. It thereby enables assessment of the robustness of
the results from the primary analysis with censoring of follow-up times for patients with
premature discontinuation.
Consideration is first given to a Kaplan–Meier multiple imputation (KMMI) procedure and
its separate invocation for the placebo group and the test treatment group. For this purpose,
we describe the KMMI strategy for a single treatment group with n patients who have the
same planned follow-up time t*. For the ith patient, we observe time Yi = min (Ti, Ci), where
Ti and Ci are the potential time to event and time to premature discontinuation (or censoring)
for the patient. We define the censoring indicator δi = I(Ti ≤ Ci), so that the data can be
summarized by (Yi, δi) for i = 1, 2 ,… , n. We assume that a study has events observed at M
distinct times (t1 < t2 < … < tM), and it has premature discontinuation of patients observed at
K distinct times (c1 < c2 < … < cK). Also, there may be more than one patient with the same
times at risk yi (i.e., occasionally tied t’s or c’s), and we assume that y = t*, δ = 0 for at least
one patient who completes the entire planned follow-up time without the event (and has
administrative censoring of their follow-up time at t*).
3.1. Kaplan–Meier Multiple Imputation Strategy
To establish the notation further, let k index the censoring times before t*. Let tk, 0 denote the
latest failure time prior to ck (or equal to it) when t1 ≤ ck, and let tk, 0 = 0 if t1 > ck. Let tk, j
denote the jth failure time after ck, j = 1, 2, … , Jk, when ck < tM. Note that the possible
values of Jk range from 1 to M, depending on the position of ck with respect to the order of
the tm’s (m = 1, 2, … , M): Jk equals M if ck < t1, and Jk equals 1 if tM−1 ≤ ck < tM. From the
data (Yi, δi), we obtain the Kaplan–Meier (KM) estimates Ŝ(t) for the survival distribution
for the event times, and it has support on the observed failure times (t1, t2, … , tM).
First, we estimate the survival rates for all K + 1 censoring times (t* and ck’s, k = 1, 2, … ,
K). For a censoring time ck followed by at least one failure time (i.e., ck < tM), the estimate
of the survival function Ŝ(ck) is defined by the straightforward convention of linear
interpolation as follows:
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In equation (1), linear interpolation is used for computational convenience and for
transparent interpretation. For the planned administrative censoring time t* > tM, (1) is not
applicable because there is not a KM estimate for Ŝ(t*)e. Nevertheless, with motivation from
a suggestion in Brown et al. (1974) to use an exponential model to extrapolate Ŝ(tM) to Ŝ(t*),
we use an exponential model for the conditional survival function for the last f events (e.g., f
= 5) as in equation (2),
(2)
to determine the corresponding hazard h from which Ŝ(t*) is computed as shown in equation
(3).
(3)
For a censoring time ck after the last failure time (i.e., tM < ck < t*), equation (3) similarly
provides Ŝ(ck) = Ŝ(tM) × exp{−h × (ck − tM)}.
Second, we construct the estimated conditional failure time distribution for each patient with
premature discontinuation. A fixed hazard ratio θ for a patient with premature
discontinuation having an event after their censoring time ck relative to the patients still
remaining on their assigned treatment is introduced as the sensitivity parameter. Thus, under
the proportional hazards assumption, the estimated survival function at time t (after ck)
equals Ŝ(t)θ. For a patient with premature discontinuation at ck < tM, the estimated
conditional probability of having the event in the time interval [tk,j, tk,j+1], for j = 1, 2, … ,
(Jk − 1), is given by
(4)
For the interval [ck, tk, 1] and [tk, Jk, t*, the estimated conditional probabilities are
(5)
respectively. Correspondingly, for a patient with premature discontinuation at ck with tM ≤
ck < t*, the estimated conditional probability of having the event in the time interval [ck, t*]
is given by
Zhao et al. Page 6























Thus, the estimate for the conditional cumulative incidence function for a patient with
premature discontinuation at ck to have the event by the time t in [tk, j < t < tk, j+1], for j = 1,
2, 3, … , Jk with tk, Jk+1 = t
* by convention, can be obtained by cumulative summation of the
 for the respective time intervals as shown in equation (7).
(7)
Under this formulation, θ> 1 (or < 1) implies a higher (or lower) hazard after ck for patients
with premature discontinuation at ck than for patients with continued follow-up after ck.
Also, θ= 1 specifies that patients with premature discontinuation and those with continued
follow-up on the assigned treatment have the same tendency to experience an event in the
future, so it is MAR-like (and in harmony with noninformative independent censoring).
Through the Cox proportional hazards model, the primary analysis can produce an estimate
 of the hazard ratio for the effect of test treatment versus placebo under the MAR-like
assumption of noninformative independent censoring for patients with premature
discontinuation. However, even if this assumption is realistic,  pertains to what would be
expected if the patients with premature discontinuation had hypothetically continued with
their assigned treatments after discontinuation. Although such a perspective may be realistic
for the placebo patients, it would usually be optimistic for the test treatment patients since
those patients are no longer receiving test treatment after premature discontinuation. Thus,
sensitivity analyses to address the implications of this issue are of interest.
One way to proceed with sensitivity analyses is to use multiple imputation with respect to
the estimated conditional cumulative incidence functions in equation (7) to impute times to
event for the patients with premature discontinuation in each treatment group. For the
placebo group, one would typically use θP = 1 under the realistic assumption that its patients
with premature discontinuation would have comparable experience after discontinuation to
their counterparts without premature discontinuation, although other specifications of θP are
feasible options. The test treatment group would usually have θT > θP specified, and with θP
= 1 θ = (θT/θP) = θT becomes a single parameter for calibrating sensitivity analyses. The
choice of can either be arbitrary, such as 1.05, 1.10, 1.15, and so on, or it can be values in a
range (L, U), where (1/U, 1/L) is a range of hazard ratios from previous related studies or
clinical judgment for the comparison of effective medicines with placebo. For example, if
previous related studies supported (1/U, 1/L) =(0.60, 0.75), then one could consider θ in the
range (1.333, 1.667) for the extent to which a test treatment patient with premature
discontinuation at ck has a higher hazard after ck than their counterparts with continuation of
test treatment after ck (in view of their treatment after discontinuation being more like
placebo than an effective treatment).
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With the conditional failure time distributions defined in equation (7), the multiple
imputation scheme is as follows:
1. Generate a random number p from the uniform distribution between 0 and 1, and
for computational convenience, use linear interpolation to impute failure times
(although exponential model interpolations are alternatively feasible).
2. Suppose a patient has premature discontinuation at ck < tM:
• If , then impute failure time  between ck and
tk, 1 as , where l indicates the lth imputation set.
• If  for j = 0, 1, 2, 3, … , (Jk − 1), then impute
failure time  between tk,j+1 and tk,j+2 as
 where tk,Jk+1 = t* by
convention.
• If , then manage the patient as having no event by the end of
follow-up time t*.
3. Suppose a patient has premature discontinuation between tM and t*, so that (tM < ck
< t*: If , then impute failure time  between ck and t* as
; otherwise, manage the patient as having no event by the end
of follow-up time t*.
4. The imputation procedure is repeated to form L imputed data sets.
The tied ck’s can be processed separately. Thus, each complete data set has no patients with
premature discontinuation, so one can apply the conventional survival analysis methods for
the primary analysis with only administrative censoring of follow-up at time t*.
In reality, most clinical trials recruit patients over a period of time and have a common
closing date. Therefore, patients always have different planned follow-up times and
correspondingly different administrative censoring times for when they could complete the
study without the event. Such staggered patient entry can be addressed by letting  denote
the planned follow-up time for the kth patient with premature discontinuation at .
For  between two consecutive failure times (tm, tm+1), the applicable survival function can
be estimated at ck and  in a fashion analogous to equation (1). For  after the last failure
time , the applicable survival function at ck and  can be estimated by the method
described for equation (3). In this way, the conditional failure time distribution can be
constructed from equations (4)-(7) according to a prematurely discontinued patient’s
planned follow-up time . The multiple imputation can then be performed in the same
fashion as discussed previously.
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The proposed method does not seek inferences for the hypothetically true parameters for
treatment effects, but rather addresses the sensitivity issues associated with the unobserved
outcomes of discontinued patients. For this purpose, the multiple imputation process regards
the observed information being fixed, that is, K and M, as well as the corresponding times to
event and times to premature discontinuation. In the context of Bayesian multiple
imputation, Rubin (1987) refers to this type of imputation as “improper,” because it does not
account for the uncertainty associated with the sample estimates (i.e., KM estimates or Cox
proportional hazards model counterparts). A way to address such uncertainty is to generate
the L data sets by separate conditional failure time distributions estimated from independent
nonparametric bootstrap resamples (with replacement) of the original data.
3.2. Parameter Estimations
The method for combining results from L imputed data sets follows well-established rules
(Rubin, 1987; Rubin and Schenker, 1991), and it can be applied easily by the SAS procedure
MIANALYZE. Let β be a scalar parameter such as a survival rate or a cumulative hazard for
a specific time point or a coefficient in the Cox proportional hazards model (i.e., the log
hazard ratio) that can be estimated from the complete data. Let  denote the point estimate
for β and let  denote its variance estimate from the lth data set. The overall multiple
imputation (MI) estimate of β is obtained by averaging the estimates from the L complete-
data analyses, , and its estimated variance is the sum of the within-
imputation  and the product of the between-imputation variance
 and the finite sample correction shown in equation (8).
(8)
Given sufficiently large sample size for the complete data to support an approximately
standard normal N(0, 1) distribution for its hypothetical version of , for which
missing data prevents availability, confidence intervals for β (and p-values for
corresponding statistical tests) can be based on  having the t-distribution with
approximate degrees of freedom (d.f.) as shown in equation (9).
(9)
Here, R expresses the relative increase in variance due to missing information. The fraction
of missing information about β is estimated as
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For nonparametric hypothesis testing with the logrank (or Wilcoxon) statistic,  is the
difference between test treatment and placebo for means of logrank or Wilcoxon scores, and
 is its estimated variance under the null hypothesis of no difference between test
treatment and placebo. It then follows that  approximately has the t-distribution
with d.f. as in equation (9). Alternatively,  can serve as  with
corresponding , in which case the statistical test would be based on  with
 with  (Taylor et al., 2002).
The term  in equation (8) and the use of the t-distribution rather than a normal
distribution widen the resulting interval estimates to account for replication variability
incurred by using L < ∞ (Schafer, 1999). Schafer (1999) suggests that unless the fraction of
missing information γ is unduly large, the widening is not substantial, and MI inferences
can be quite efficient even when L is small (usually less than 10). Nevertheless, in practice,
the appropriate number of imputations should be investigated more closely, especially when
the fraction of missing information is large (Horton and Lipsitz, 2001).
4. RESULTS
4.1. Performance of KMMI Method Under θ = 1
In this section, we consider the performance of the KMMI method with θ = 1 for the clinical
trial in section 2. With this specification, the imputed data are produced from the same
conditional failure time distributions as estimated by the KM method with censoring of the
follow-up times of patients with premature discontinuation, and it thereby has the same
MAR-like assumption of noninformative independent censoring. To apply this method, we
proceed in accordance with Horton and Lipsitz (2001) to determine the appropriate number
of imputations (L) by evaluating the stability of an estimator and its standard errors (SE)
with respect to the different L’s. Multiple imputations are performed separately for each of
the two treatment groups with θ = 1, and 100 replicates of imputations are produced for each
of the following numbers of imputations (L = 3, 5, 10, 20, 30, 40, 50, 70, and 100); thus,
there are seven different sets of imputations. The variabilities of the estimates for the
survival function at the 20th week are summarized in boxplots in Fig. 2 relative to the
conventional KM estimates (with censoring of follow-up times for patients with premature
discontinuation). The relative variance increases due to missing data
 corresponding estimates are summarized in Fig. 3. Compared to
the conventional KM estimates, the mean values of estimates from the KMMI method are
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somewhat smaller for all seven sets of imputations. Also, the KMMI estimates and the
corresponding R in Fig. 2 and Fig. 3 (for the 20-week survival rate) are not stable for small
numbers of imputations (i.e., L ≤ 10). The variability of the MI estimates becomes smaller as
the number of imputations increases, and stabilizes near L = 50 or higher for both treatment
groups. Thus, 50 imputations is a reasonable choice for the amount of missing information
which this example has. Although a comprehensive simulation study could shed more light
on the choice of L for different extents of missing data, such research is beyond the scope of
this paper. Nevertheless, for any real study, the specification of at least a moderately high
value of L ≥ 50 should be considered, especially given the simplicity of the computations
even for large L.
We apply multiple imputation (MI) with L = 50 henceforth. The conventional KM curves for
both treatment groups are shown in Fig. 4(a) with their counterparts from averaging the KM
estimates for 50 data sets imputed by the KMMI method. The corresponding cumulative
hazard curves (via the Aalen–Nelson estimator) are shown in Fig. 4(b). The relationships
shown for the KMMI method are almost identical to their conventional counterparts. In row
2A of Table 3, results from the KMMI method are shown for the hazard ratio for the effect
size of the test treatment versus placebo from the unadjusted Cox proportional hazards
model (which only includes treatments), as well as for the p-values for the logrank test and
the Wilcoxon test. Interestingly, the estimated hazard ratio from the KMMI method is closer
to unity (and thus is a smaller effect size) and has a somewhat larger p-value than its
conventional counterpart with the use of censoring (HR = 0.724 with p = 0.0436 for KMMI
versus HR = 0.675 with p = 0.0140 for conventional). This disagreement between the
inference for the effect of the test treatment from the KMMI method with θ = 1 and
conventional counterparts with censoring could be a consequence of nonproportional
hazards during the follow-up period. As can been seen from the survival curves in Fig. 4(a)
and the cumulative hazard curves in Fig. 4(b), the difference between the two treatment
groups is most clearly evident during the early stage of the follow-up and less apparent later.
This issue is explored further by partitioning the follow-up period into four distinct intervals
with approximately equal numbers of events, and then producing conventional interval-
specific hazard ratio estimates for each of them from an unadjusted Cox proportional
hazards model. The results of such analysis in Table 3(1) suggest much stronger effect sizes
for test treatment during 0–6 weeks than during 6–76 weeks, so they are contrary to the
hazard ratio being constant during the entire follow-up period.
When treatment is the only explanatory variable in the Cox proportional hazards regression
model, its estimated effect size is approximately an average of log HR over the entire
follow-up period. When there are many patients with premature discontinuation, the
estimation of the average log HR through conventional methods with censoring may tend to
be mainly influenced by events during the earlier part of the follow-up period (where the
effect sizes for test treatment are stronger for this example). The KMMI method eliminates
censoring during the follow-up period by imputing potential times to event for every patient
with premature discontinuation, and it thereby puts more weight on what happens during the
latter part of the follow-up period (where the effect sizes for test treatment are smaller for
this example), so it produces a smaller effect size for test treatment (in the sense of an
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estimated hazard ratio that is closer to unity). Thus, this example suggests that the sensitivity
analysis with θ = 1 for the KMMI method can be useful for evaluating the implications of
nonproportional hazards during the follow-up period.
An alternative structure for multiple imputation is provided by the Breslow estimators of the
survival distributions for the placebo and test treatment groups from the Cox proportional
hazards model with treatment as the only explanatory variable, and it can have
implementation through its counterparts for equations (1)–(7). As shown in Table 3, rows
1A and 3A, the proportional hazards multiple imputation (PHMI) method under θ = 1
provides results very similar to the conventional methods with censoring, mainly because
both operate under the MAR-like assumption of noninformative independent censoring and
both have the proportional hazards assumption.
We further consider an imputation with nonparametric bootstrap resampling so as to add
extra between-imputation variability and thereby to be in better harmony with a “proper”
imputation. Consequently, L may need to be much larger than 50, in order to provide
appropriate precision for estimation. Both the KMMI and the PHMI methods proceed with
an additional bootstrap step for L = 50, L = 100, and L = 500. The results of MI with the
bootstrap for L = 500 are relatively consistent with the methods without the bootstrap for L =
50 (see Table A-1 for details). The bootstrap KMMI method uses separate samples with
replacement for each treatment group, and its results for L = 500 (Table 3.4A) are slightly
weaker compared with its counterparts without the bootstrap for L = 50. The PHMI method
with the bootstrap uses samples with replacement from the combined treatment groups. As
shown in Table 3.5A, when performed for L = 500, the PHMI with the bootstrap produces
comparable results to the PHMI without the bootstrap for L = 50. The imputation methods
with and without the bootstrap arise from different paradigms. The imputation methods with
the bootstrap are based on Bayes’s theory and relate the posterior distribution given the
observed data to the complete posterior distribution given no missing data in a random
sample of a target population, and therefore they add more complexity to the imputation
process. Alternatively, the methods without the bootstrap address the uncertainty of missing
data in the context of the observed information being known and fixed. Depending on the
purpose of the sensitivity analysis, either process can be applied. For this article, we
emphasize the sensitivity analysis using the MI methods without the bootstrap for L = 50.
4.2. Sensitivity Analysis
The sensitivity analyses proceed with varying θ (for the test treatment) in a plausible range
from 1 to 2.5 (with θ = 1 for placebo) to determine how the assessment of the treatment
effect changes for the different extents of imputed events for patients with premature
discontinuation at specific times ck versus patients with continued follow-up beyond those
times. In this regard, θ = 2.5 = 1/0.4, and 0.4 might represent a reasonably large effect size
for a clearly effective treatment versus placebo in the published clinical literature for
maintenance treatments of bipolar disorder. On this basis, it is a reasonable choice for the
upper bound of the sensitivity parameter θ in terms of how much more rapidly the patients
that had premature discontinuation would have the event compared to those that did not; in
this regard, it is useful to note that θ = ∞ corresponds to the worst–comparison analysis.
Zhao et al. Page 12






















The value of θ is varied by 0.01 increments from 1 to 2.5, leading to 150 treatment effect
assessments. Contour plots of the hazard ratio estimates and the p-values for treatment
comparisons are then constructed as a function of the sensitivity parameter θ. We implement
both the KMMI method and the PHMI method in these sensitivity analyses. The multiple
imputation results from the Cox proportional hazards models, as well as the logrank and
Wilcoxon tests are combined using the method described in section 3.2.
The sensitivity analysis results using the KMMI method are summarized in Fig. 5. The
values of θ plotted against the estimated hazard ratios with 95% confidence intervals are
shown in Fig. 5a, and the p-values obtained from the Wald test from the Cox proportional
hazards model, the logrank test, and the Wilcoxon test are shown in Fig. 5b. The magnitude
of the estimated treatment effect moves closer to the null (i.e., θ = 1) as the value of θ
increases. The HR estimates for test treatment versus placebo have a range from 0.724 (for θ
= 1) to 0.867 (for θ = 2.5). The corresponding p-values from the Wald test vary substantially
over the range of θ, indicating that the assumptions for patients with premature
discontinuation can substantially influence study conclusions. As expected, the p-values
from the Wald test agree with those from the logrank test, and they are larger than those
from the Wilcoxon test. In order to have p ≤ 0.05 with the Wald test (or the logrank test), θ
≤ 1.08 (or 1.05) is needed, with this specification being only slightly more stringent than the
MAR-like assumption of non-informative independent censoring (or θ = 1). For the
Wilcoxon test, p ≤ 0.05 applies with θ ≤ 2.08, so it has better robustness to assumptions
about patients with premature discontinuation of treatment for this example than the Wald
test or the logrank test. Since the Wilcoxon test receives relatively more weight than the
logrank test for early failures and relatively less weight for later failures, it is more able to
detect the early hazard differences for this example than the logrank test. As shown in Fig.
4b and Table 3(1), the estimated treatment effect is much stronger (i.e., hazard ratios are
further away from 1) in the earlier part of the follow-up.
The results of sensitivity analyses with the PHMI method are shown in Fig. 6. Because the
PHMI method invokes the possibly unrealistic proportional hazards assumption, it suggests
better robustness for the conclusions from the Cox proportional hazards model and the
logrank test than the KMMI method. For p ≤ 0.05 with the Wald test (or the logrank test), θ
≤ 1.59 (or 1.58) is needed; also, for the Wilcoxon test, p ≤ 0.05 applies for all θ ≤ 2.5. In
general, the PHMI method may not always suggest stronger conclusions than the KMMI
method. When the differences between the test treatment and the placebo are more
substantial during the latter part of the follow-up period than during the early part, the
KMMI method with θ = 1 could lead to stronger conclusions (i.e., estimated hazard ratios
further from 1 and smaller p-values), while the PHMI method under θ = 1 would tend to
produce similar results as conventional analyses with censoring of follow-up time for
patients with premature discontinuation. Therefore, the sensitivity analysis based on the
KMMI method may provide more accurate assessment than the PHMI method.
Sensitivity analyses with both the KMMI and the PHMI methods can be useful for reviewers
to understand the robustness of conclusions for treatment effects to the assumptions of
noninformative independent censoring and proportional hazards. The degree to which
conclusions are stable across a reasonable range of θ provides an indication of the
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confidence that can be placed on them. Opinions on possible values of θ can be based on
knowledge from other studies for similar interventions. An investigation of the differences
between baseline characteristics of completers and patients with premature discontinuation
can be useful, as well as the reasons for discontinuation. If such information suggests that
only unrealistic values of θ would alter study conclusions, then the results of a primary
analysis with conventional methods could be considered robust from a clinical perspective.
When the inference about treatment effects could be overturned for plausible values of θ,
then it should be viewed with caution.
5. DISCUSSION
Analysis of incomplete data is a challenge for most clinical trials. Often, MAR-like
assumptions about the missing data mechanism can be reasonable for primary analyses.
However, the possibility of MNAR is difficult to rule out, particularly when patients with
test treatment lose its benefit after discontinuation, so sensitivity analyses for alternative
ways to address missing data become of interest.
In time-to-event analyses, patients with premature discontinuation have their follow-up time
censored at the time of discontinuation, and the usual assumption is noninformative
independent censoring. As right-censoring is a special case of coarsened data, the
assumption of noninformative independent censoring can be generalized to “coarsened at
random,” which extends the concept of MAR to coarsened data (Heitjan, 1994). The MNAR
issue for time-to-event data is to account properly for censoring that may be informative.
Most sensitivity analyses in the literature assess the effect of various assumptions
concerning the dependence between failure and censoring times (Scharfstein and Robins,
2002; Siannis et al., 2005; Ruan and Gray, 2008). However, clinical reviewers can have
difficulty in understanding the interpretation of the sensitivity parameters in those analyses,
and this can make the specification of reasonable ranges for the sensitivity parameter
challenging.
This article discusses sensitivity analyses for time-to-event data, and its suggested methods
can have several appealing features in regulatory clinical trial settings. First, they enable
direct exploration of the effect of departures from the noninformative independent censoring
assumption for conventional methods (such as Cox proportional hazards models, logrank
tests, and Wilcoxon tests) through a sensitivity parameter that connects the unobserved
outcomes and the observed outcomes, that is, a hazard ratio for a discontinued patient
having an event after discontinuation relative to the patients remaining on their assigned
treatment. The multiple imputation strategy is straightforward because the predictive
distributions are specified directly, and they do not depend on the models for assumed
missingness mechanisms. The interpretation of the sensitivity parameter is transparent in the
sense that the parameter is based on a standard criterion for analyzing time-to-event data,
and consequently may be more understandable to reviewers. Second, the sensitivity analysis
accounts for all randomized patients. The specifications for post-discontinuation experience
are intended to address the question for what the long-term benefit of initial assignment
would be if patients with premature discontinuation were followed to the end of the study
without other treatment. In addition, the influence of departures from the noninformative
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independent censoring assumption with respect to patients with premature discontinuation
can be assessed either simultaneously with the proportional hazards assumption by the
KMMI method or separately in its own right by the PHMI method. Third, the sensitivity
analysis is based on multiple imputation of missing outcomes, and therefore it provides a
simple way of generating statistical inference without the need of special software and
programming. All of the analyses presented in this article can be produced by standard SAS
PROC procedures and SAS macros. Finally, the proposed sensitivity analysis anchors on a
primary MAR-like assumption, and then can have calibration toward the worst comparison
analysis through how it penalizes premature discontinuation for the test treatment. The
method can be specified a priori and does not require any post hoc (i.e., data–driven)
revisions. Therefore, this type of sensitivity analysis to address the missing information from
censored follow-up times could be attractive in the regulatory environment.
The sensitivity analysis illustrated here was performed for a continuous time-to-event
endpoint. However, the methodology and underlying principles can be extended to
categorical (or interval censored) time-to-event data. Furthermore, the proposed PHMI
strategy can be modified to incorporate the information of patients’ baseline risk factors.
One can estimate the failure time distributions separately for subpopulations defined by
baseline covariates and treatments through the multivariate Cox proportional hazards model
that includes treatments and the set of covariates as explanatory variables. The conditional
failure time distributions can then be used for risk–adjusted multiple imputations. Currently,
the discussed MI strategies invoke separate imputations for each of the two groups with its
corresponding survival distribution estimates. An alternative approach is to impute times to
event for both treatment groups using the information in the placebo group. The details of
this method and its corresponding results are discussed in the appendix. However, it may not
address robustness as stringently as the methods that are the main focus of this article, when
the placebo group has a higher proportion of discontinuations than the test treatment group.
Typically, the design of a confirmatory trial should account for the loss of power from
patients with premature discontinuation (National Research Council, 2010). An often-used
approach is simply to inflate the initially planned sample size by the reciprocal of one minus
the anticipated premature discontinuation rate, but this may only be reasonable if missing
information is MCAR. Power calculations should be based on more plausible MAR-like
assumptions, and perhaps accommodating the situations of MNAR and the potentially
reduced effect size estimation in sensitivity analyses. However, those concerns usually
cannot be addressed analytically in sample size calculations. The multiple imputation
strategy presented in the current sensitivity analysis method can be adapted for simulation-
based power calculations to assess the effect of missing data on sample size.
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6. APPENDIX
6.1. Graphical Displays for the Cumulative Discontinuation Proportions by
Documented Reasons
Figure A-1.
Cumulative discontinuation proportions by documented reasons
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6.2. Results from the KMMI and PHMI Methods With/Without Bootstrap
Resampling at θ = 1
Table A-1
KMMI and PHMI methods with/without bootstrap resampling at θ = 1
Semi-parametric analysis (Cox PH model)
Analysis method Coefficient Std Err
b




1. L = 50
KMMI without bootstrap -0.322 0.160 0.724 (0.530, 0.991) 0.0436 0.0451 0.0109
KMMI with bootstrap -0.325 0.180 0.723 (0.507, 1.030) 0.0727 0.0770 0.0167
PHMI without bootstrap −0.388 0.158 0.678 (0.497, 0.925) 0.0143 0.0145 0.0053
PHMI with bootstrap -0.389 0.165 0.678 (0.490, 0.938) 0.0191 0.0204 0.0068
2. L = 100
KMMI without bootstrap -0.328 0.159 0.720 (0.527, 0.984) 0.0394 0.0410 0.0101
KMMI with bootstrap −0.347 0.178 0.707 (0.498, 1.003) 0.0519 0.0550 0.0127
PHMI without bootstrap −0.394 0.158 0.674 (0.495, 0.918) 0.0124 0.0126 0.0048
PHMI with bootstrap −0.399 0.164 0.671 (0.486, 0.925) 0.0150 0.0157 0.0056
3. L = 500
KMMI without bootstrap −0.332 0.156 0.717 (0.528, 0.974) 0.0332 0.0345 0.0091
KMMI with bootstrap −0.336 0.170 0.714 (0.512, 0.997) 0.0480 0.0507 0.0114
PHMI without bootstrap −0.398 0.156 0.672 (0.495, 0.911) 0.0106 0.0108 0.0044
PHMI with bootstrap −0.396 0.160 0.673 (0.492, 0.921) 0.0134 0.0140 0.0053
a
P-Values of hypothesis test.
b
Standard error.
6.3. Alternative KMMI Strategy for Sensitivity Analysis
An alternative way to perform sensitivity analysis is to use the information in the placebo
group to impute times to event for both treatment groups using the KMMI approach. To
generate one set of the L imputed data, one could first impute failure time for discontinued
patients in the placebo group under certain specification of θp; the KM estimates obtained
from those complete data in the placebo group are then used to perform imputation through
equations (1)–(7) for the discontinued patients in the test treatment group. In this MI
procedure, the sensitivity parameter θ only needs to be specified for the placebo group.
Besides choosing θp = 1 to approximate a MAR-like assumption, θp > 1 can be used to
address the possibility that the post-discontinuation experience is less favorable than the
patients remaining on their assigned treatment. The results of sensitivity analysis at L = 50
under various specifications of θp are shown in Table A-2. For this particular example, the
estimated treatment effect when θp = 1 is slightly weaker than those from applying the
KMMI method within individual treatment groups with θ = 1 for both (Table 3.2A). As the
value of θP increases, results in favor of the test treatment become stronger, because the
placebo group has more prematurely discontinued patients than the test treatment group, and
thereby θp > 1 penalizes the placebo group more.
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Alternative KMMI strategy for sensitivity analysis
Semi-parametric analysis (Cox PH model)
θp Coefficient Std Err
b




1 −0.135 0.155 0.730 (0.538, 0.990) 0.0430 0.0440 0.0131
1.1 −0.332 0.154 0.717 (0.530, 0.971) 0.0313 0.0322 0.0097
1.2 −0.346 0.153 0.708 (0.524, 0.956) 0.0241 0.0248 0.0075
1.3 −0.361 0.150 0.697 (0.519, 0.935) 0.0160 0.0164 0.0053
1.4 −0.368 0.150 0.692 (0.516, 0.928) 0.0140 0.0143 0.0043
1.5 −0.384 0.151 0.681 (0.507, 0.916) 0.0110 0.0113 0.0033
a
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Cumulative discontinuation proportions by treatment groups.
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Distributions of 20-week survival rates for 100 replications of different numbers of imputations. The conventional KM estimates
are indicated with the horizontal line.
Zhao et al. Page 21























Distributions of relative variance increase due to missing data (R) of 20-week survival rates for 100 replications of different
numbers of imputations.
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Comparison of the results from the conventional (MAR-like) and the KMMI method.
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Sensitivity analysis results using KMMI method.
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Figure 6. Sensitivity analysis results using PHMI method
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Table 1
Discontinuations and the corresponding reasons by treatment groups
Treatment group
Overall Placebo Test treatment
Disposition N % N % N %
Completed study without episode 46 15.33 15 10.00 31 20.67
Intervention for a mood episode 157 52.33 82 54.67 75 50.00
Discontinued study prematurely 97 32.33 53 35.33 44 29.33
  Adverse event 24 8.00 16 10.67 8 5.33
  Consent withdraw 28 9.33 13 8.67 15 10.00
  Lost to follow-up 20 6.67 8 5.33 12 8.00
  Protocol violation 10 3.33 3 2.00 7 4.67
  Other (including missing data) 15 5.00 13 8.67 2 1.33
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Table 2
Unadjusted and adjusted odds ratios for discontinuation













(95% CI) P value
Treatment (test
 vs. placebo)
−0.275 (0.248) 0.76 (0.47, 1.23) 0.2671 −0.242 (0.253) 0.79 (0.48, 1.29) 0.3398
Age (1 year
 increment)
−0.012 (0.010) 0.99 (0.97, 1.01) 0.2423 −0.011 (0.011) 0.99 (0.97, 1.01) 0.2941
Gender (female
 vs. male)






0.301 (0.208) 1.35 (0.90, 2.03) 0.1474 0.584 (0.337) 1.79 (0.93, 3.47) 0.0828
Pre-rand CGI-S
 score
0.021 (0.168) 1.02 (0.74, 1.42) 0.9018 −0.348 (0.277) 0.71 (0.41, 1.21) 0.2085
Pre-rand GAS
 score
−0.002 (0.012) 1.00 (0.98, 1.02) 0.8719 0.010 (0.017) 1.01 (0.98, 1.04) 0.5580
Pre-rand MRS 11
 item total score
−0.012 (0.047) 0.99 (0.90, 1.08) 0.7962 −0.036 (0.050) 0.96 (0.87, 1.06) 0.4690
Pre-rand MRS 17
 item total score








One unit increment for all score variables.
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